Dactolisib: all 24 studies that test it

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• A Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the ElderlyCompletedNCT04668352Phase 3Results posted
• A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate CancerTerminatedNCT01717898Phase 1/2Results posted
• BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.CompletedNCT01658436Phase 2Results posted
• Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine TumorsTerminatedNCT01628913Phase 2Results posted
• BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)TerminatedNCT01453595Phase 1/2Results posted
• A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older AdultsActive, not recruitingNCT04584710Phase 2
• Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing HomesTerminatedNCT04409327Phase 2
• Effect of RTB101 on Illness Associated With Respiratory Tract Infections in the ElderlyWithdrawnNCT04139915Phase 3
• Dose Finding Study to Determine if BEZ235 Alone or in Combination With RAD001 Decreases the Incidence of Respiratory Tract Infections in the ElderlyActive, not recruitingNCT03373903Phase 2
• Study of BEZ235 as Monotherapy in Patients With Transitional Cell Carcinoma After Failure of Platinum Based ChemotherapyTerminatedNCT01856101Phase 2
• A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute LeukemiaCompletedNCT01756118Phase 1
• A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComaWithdrawnNCT01690871Phase 2
• Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) PatientsCompletedNCT01634061Phase 1
• Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid TumorsTerminatedNCT01508104Phase 1
• Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast CancerTerminatedNCT01495247Phase 1/2
• Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid TumorsCompletedNCT01482156Phase 1
• Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid TumorsCompletedNCT01343498Phase 1
• Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor PatientsCompletedNCT01337765Phase 1
• BEZ235 Trial in Patients With Advanced Endometrial CarcinomaWithdrawnNCT01290406Phase 2
• BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast CancerWithdrawnNCT01288092Phase 2
• A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without TrastuzumabCompletedNCT01285466Phase 1
• PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast CancerCompletedNCT01248494Phase 1
• A Study of BEZ235 in Adult Japanese Patients With Advanced Solid TumorsCompletedNCT01195376Phase 1
• A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast CancerCompletedNCT00620594Phase 1

← Dactolisib overview